Transcriptional Targeting of Dendritic Cells Using an Optimized Human Fascin1 Gene Promoter

Area of Science:

• Immunology
• Molecular Biology
• Cancer Research

Background:

• The tumor microenvironment (TME) plays a crucial role in cancer progression, driving the development of novel immunotherapies.
• Gene-based cancer immunotherapies, including DNA vaccines, aim to elicit anti-tumor immune responses.
• Optimizing DNA vaccine efficacy and selectivity, particularly targeting antigen-presenting cells like dendritic cells (DCs), is essential.

Purpose of the Study:

• To investigate the concept of DC-focused transcriptional targeting for DNA vaccines.
• To evaluate a novel plasmid construct (pFscnLuc) designed for DC-specific gene expression.
• To compare the activity of the novel construct against a standard ubiquitous promoter in vitro and in vivo.

Main Methods:

• Constructed a plasmid (pFscnLuc) using a derivative of the human fascin1 gene promoter fused to a DC enhancer region.
• Assessed reporter gene expression in cell culture using luciferase assays, comparing pFscnLuc with a cytomegalovirus promoter-driven vector (pCMVLuc).
• Administered plasmids intravenously in mice and analyzed organ- and cell type-specific expression profiles.

Main Results:

• The pFscnLuc construct demonstrated DC-focused activity in cell culture compared to the pCMVLuc vector.
• In vivo studies in mice showed preferential expression of pFscnLuc in the spleen, a key immune organ.
• Within the spleen, pFscnLuc exhibited specific activity in dendritic cells.

Conclusions:

• The developed DC-focused transcriptional targeting strategy shows promise for enhancing DNA vaccine selectivity.
• The fascin1 promoter derivative effectively directs gene expression to DCs, particularly in the spleen.
• This approach may lead to more effective and targeted cancer immunotherapies.